Skip to content

Study · Randomized controlled trial · n = 410 · 2011

5 results

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK

AIDS (London, England)1 Jun 2011Cited by 14 (Europe PMC)

PMID21516030 (opens in a new tab)PMCIDPMC3673013 (opens in a new tab)DOI10.1097/qad.0b013e328347f3f1 (opens in a new tab)PepBankPUB-21516030
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In HIV-infected patients with abdominal adiposity, tesamorelin decreased tPA antigen from baseline more than placebo.

    In plain wordsIn HIV-infected patients with abdominal fat, tesamorelin lowered the clotting-related marker tPA more than placebo.

    Peptide
    Tesamorelin
    Outcome
    DecreasetPA antigen change
    Study

    n = 410

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    tPA antigen change
    −2.2 ng/ml
    tesamorelin
    tPA antigen change
    −1.6 ng/ml
    placebo

    Source sentences

    Summary
    Treatment with tesamorelin resulted in a significant decrease from baseline in tPA antigen (-2.2 ± 2.5 vs. -1.6 ± 2.9 ng/ml, tesamorelin vs. placebo, P < 0.05).
    1 context sentence
    Summary · context
    Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In HIV-infected patients with abdominal adiposity, the change in PAI-1 antigen with tesamorelin was not significant compared with placebo.

    In plain wordsIn HIV-infected patients with abdominal fat, the clotting-related marker PAI-1 did not change significantly with tesamorelin compared with placebo.

    Peptide
    Tesamorelin
    Outcome
    No significant changePAI-1 antigen change
    Study

    n = 410

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Changes in PAI-1 antigen were not significant in the tesamorelin group compared to placebo.
    1 context sentence
    Summary · context
    Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks.
  3. 03HumanRandomized controlled trialMechanism

    In HIV-infected patients receiving tesamorelin, changes in PAI-1 antigen were positively associated with changes in VAT, independent of IGF-1 change.

    In plain wordsIn HIV-infected patients on tesamorelin, changes in the marker PAI-1 were linked to changes in belly fat.

    Peptide
    Tesamorelin
    Outcome
    Not applicableAssociation of PAI-1 antigen change with VAT change
    Study

    n = 273

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Spearman rho
    0.16
    PAI-1 vs VAT change

    Source sentences

    Summary
    Among patients receiving tesamorelin, changes in inflammatory markers were associated with change in VAT (PAI-1 antigen: ρ = 0.16, P = 0.02; tPA antigen: ρ = 0.16, P = 0.02; adiponectin: ρ = -0.27, P < 0.001), and these associations remained significant when controlling for changes in insulin-like growth factor-1.
    1 context sentence
    Summary · context
    Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks.
  4. 04HumanRandomized controlled trialMechanism

    In HIV-infected patients receiving tesamorelin, changes in tPA antigen were positively associated with changes in VAT, independent of IGF-1 change.

    In plain wordsIn HIV-infected patients on tesamorelin, changes in the marker tPA were linked to changes in belly fat.

    Peptide
    Tesamorelin
    Outcome
    Not applicableAssociation of tPA antigen change with VAT change
    Study

    n = 273

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Spearman rho
    0.16
    tPA vs VAT change

    Source sentences

    Summary
    Among patients receiving tesamorelin, changes in inflammatory markers were associated with change in VAT (PAI-1 antigen: ρ = 0.16, P = 0.02; tPA antigen: ρ = 0.16, P = 0.02; adiponectin: ρ = -0.27, P < 0.001), and these associations remained significant when controlling for changes in insulin-like growth factor-1.
    1 context sentence
    Summary · context
    Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks.
  5. 05HumanRandomized controlled trialMechanism

    In HIV-infected patients receiving tesamorelin, changes in adiponectin were negatively associated with changes in VAT, independent of IGF-1 change.

    In plain wordsIn HIV-infected patients on tesamorelin, adiponectin changes were linked in the opposite direction to changes in belly fat.

    Peptide
    Tesamorelin
    Outcome
    Not applicableAssociation of adiponectin change with VAT change
    Study

    n = 273

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2 mg · subcutaneous · 26 weeksAs given in this study (human).

    Measurements

    Spearman rho
    −0.27
    adiponectin vs VAT change

    Source sentences

    Summary
    Among patients receiving tesamorelin, changes in inflammatory markers were associated with change in VAT (PAI-1 antigen: ρ = 0.16, P = 0.02; tPA antigen: ρ = 0.16, P = 0.02; adiponectin: ρ = -0.27, P < 0.001), and these associations remained significant when controlling for changes in insulin-like growth factor-1.
    1 context sentence
    Summary · context
    Four hundred and ten HIV-infected patients with abdominal adiposity were randomized to 2 mg tesamorelin (n = 273) or placebo (n = 137) subcutaneously daily for 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.